Good news: Novavax’s COVID vaccine starts Phase III trials 

WASHINGTON (AP) – A huge study of another COVID-19 vaccine candidate is getting underway Monday as states in the U. S. continue to roll out scarce supplies of the nation’s first shot options. The U. S. has authorized the emergency use of two vaccines, one made by Pfizer and BioNTech and the other by Moderna, but doses will be rationed for months. The candidate made by Novavax Inc. is the fifth to reach final-stage testing in the U. S.

Source: Novavax’s COVID vaccine to be studied in the US | KATU

Their vaccine shipments are probably 5-6 months out, assuming their trials go well. The US government has contracted with Novavax but their supply not likely to kick in until summer of 2021.

Interesting quote from Dr Fauci who has been saying the “general public” can get vaccines starting in April (even though we have only enough to dose about 1/3 of the population by April):

“If you want to have enough vaccine to vaccinate all the people in the U.S. who you’d like to vaccinate – up to 85% or more of the population – you’re going to need more than two companies,” Dr. Anthony Fauci, the top U.S. infectious disease expert, told The Associated Press.

Finally, Biden may invoke the Defense Production Act to increase vaccine production. An acknowledgement that vaccines may be in short supply until summer, unless new production occurs.